GLPBio

Equol

Catalog No.: GC16292Purity:>98.00%
L'équol est le racémate de l'équol.

Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.


Equol
Cas No.: 94105-90-5
10mM (in 1mL DMSO)In Stock
$35.00
1
5mgIn Stock
$30.00
1
25mgIn Stock
$88.00
1

Citations

1 publicationsPublications de chercheurs utilisant ce produit

Description

IC50: Not available.

Equol is an isoflavan produced by intestinal bacteria in response to soy isoflavone intake in human. It shows a wide range of activities including antioxidant activity, anti-inflammation activity and anticancer activity. It is reported that Equol specifically binds to 5α-DHT and has a modest affinity for recombinant estrogen receptor ERβ, which may be responsible for most of Equol’s biological properties. [1]

In vitro: In vitro studies were conducted to measure both the binding affinity of Equol for 5alpha-dihydrotestosterone (5alpha-DHT) and the effects of Equol treatment in human prostate cancer (LNCap) cells. It was found that Equol bound to 5alpha-DHT with maximum and half maxim concentrations of 100 nM and 4.8 nM, respectively. In addition, Equol significantly offset the increases in PSA levels from LNCap cells. [1]

In vivo: An in vivo study was performed to investigate effects of equol on rat prostate weight and circulating levels of sex steroid hormones. 1.0 mg/kg of Equol was injected to Long-Evans rats fed with a low isoflavone diet for 25 days. Findings from this study suggested that Equol significantly decreased rat prostate weights and down-regulated serum levels of 5alpha-DHT. However, this agent did not alter levels of LH, testosterone and estradiol. [1]

Clinical trials: A clinical study on hypercholesterolemic patients demonstrated that, after 4 weeks’ dietary intervention with a soy isoflavone-containing food, brachial artery-mediated vasodilatation in equol-producers was notably higher when compared with that in equol-nonproducers. Similar differential effects between equol-producers and nonproducers were aslo reported in arterial stiffness from a study on postmenopausal women taking tibolone. [2]

References:
[1]Lund TD, Blake C, Bu L, Hamaker AN, Lephart ED.  iEquol an isoflavonoid: potential for improved prostate health, in vitro and in vivo evidence. Reprod Biol Endocrin. 2011; 9(4): doi: 10.1186/1477-7827-9-4.
[2]Setchell DR and Clerici C.  Equol: Pharmacokinetics and biological actions. J Nutr. 2010 Jul; 140(7): 1363S–8S.

Protocole (Protocol)

Cell experiment:

Primary rat osteoblasts are treated with 0.01-1 μM equol, 0.01-1 μM E2 , or 0.01-1 μM equol/E2 combined with 1 μM ICI182780 for 24 or 48 hours. Then 10 mL 5 mg/mL MTT solution is added to each well. The plates are incubated at 37°C for 4 h, and then the supernatant is discarded and 100 mL DMSO is added to each well and mixed thoroughly before taking measurements in a microplate reader[3].

Animal experiment:

Rats: Equol or furosemide is administered orally at doses of 16, 40, and 100 mg/kg (in a volume of 16 mL/kg 5% arabic syrup) to groups of 3-9 rats (rats of a control group are administered vehicle only). Urine samples are collected for 6 h. Urinary sodium and potassium contents are measured by flame photometry[3]. Mouse: Equol is dissolved in water and administered orally to rats at a dose of 5 and 25 mg/kg BW for 8 weeks after a single dose of DMBA (100 mg/kg). As controls, rats are divided into vehicle alone and DMBA alone groups. In the second part, ICR mice are orally administered equol daily at a dose of 5 and 25 mg/kg BW for 7 weeks before a single dose of DMBA (34 mg/kg/week). After equol administration animals are followed for 1 week continuously. The control groups are the same as above and each group are comprised of six mice. Mice livers and mammary gland tumors are isolated, blotted, weighed, frozen in liquid nitrogen and stored at -70°C until assayed[5].

References:

[1]. Axelson M, et al. The identification of the weak oestrogen equol [7-hydroxy-3-(4'-hydroxyphenyl)chroman] in human urine. Biochem J. 1982 Feb 1;201(2):353-7.
[2]. Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. human intestinal bacterial flora.
[3]. Wang J, et al. Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor. Genet Mol Res. 2014 Jul 4;13(3):5055-63.
[4]. Gimenez I,et al. Renal and vascular actions of equol in the rat. J Hypertens. 1997 Nov;15(11):1303-8.
[5]. Choi EJ, et al. Anticancer mechanism of equol in 7,12-dimethylbenz(a)anthracene-treated animals. Int J Oncol. 2011 Sep;39(3):747-54.

Documents produit (Product Documents)

Purity:>98.00%Appearance:A solid

Propriétés chimiques (Chemical Properties)

N° CAS
94105-90-5
Nom chimique
(3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
SMILES
C1C(COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O
Formule moléculaire
C15H14O3
Masse moléculaire
242.27
Solubilité
≥ 12.1mg/mL in DMSO
Conservation
Store at -20°C
Conseils généraux
Choisissez un solvant adapté selon les données de solubilité du produit. Après préparation, répartissez la solution mère en aliquotes afin d’éviter les cycles répétés de congélation-décongélation.
Utilisez les solutions mères dans les 6 mois si elles sont conservées à -80°C, ou dans le mois si elles sont conservées à -20°C.
Pour améliorer la solubilité, réchauffez le tube à 37°C et soniquez-le pendant une durée appropriée.
Conditions d’expédition
Les échantillons d’évaluation sont expédiés avec des blocs réfrigérants. Les autres formats sont expédiés à température ambiante ou, sur demande, avec des blocs réfrigérants.

Calculateurs (Calculators)Molarité / Dilution / Masse moléculaire / Conversion d’unités / Formulation in vivo / Solubilité

g/mol

Reviews

Review for Equol

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%